These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 11056104

  • 1. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats.
    Sakata Y, Masuyama T, Yamamoto K, Nishikawa N, Yamamoto H, Kondo H, Ono K, Otsu K, Kuzuya T, Miwa T, Takeda H, Miyamoto E, Hori M.
    Circulation; 2000 Oct 31; 102(18):2269-75. PubMed ID: 11056104
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
    Takeda Y, Yoneda T, Demura M, Usukura M, Mabuchi H.
    Circulation; 2002 Feb 12; 105(6):677-9. PubMed ID: 11839620
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
    Kobayashi M, Machida N, Mitsuishi M, Yamane Y.
    Am J Hypertens; 2004 Dec 12; 17(12 Pt 1):1112-9. PubMed ID: 15607617
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart.
    Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Hori M.
    J Hypertens; 2002 Apr 12; 20(4):753-61. PubMed ID: 11910313
    [Abstract] [Full Text] [Related]

  • 9. Endothelin-A receptor blockade prevents left ventricular hypertrophy and dysfunction in salt-sensitive experimental hypertension.
    Rothermund L, Vetter R, Dieterich M, Kossmehl P, Gögebakan O, Yagil C, Yagil Y, Kreutz R.
    Circulation; 2002 Oct 29; 106(18):2305-8. PubMed ID: 12403658
    [Abstract] [Full Text] [Related]

  • 10. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy.
    Chang SA, Kim YJ, Lee HW, Kim DH, Kim HK, Chang HJ, Sohn DW, Oh BH, Park YB.
    Hypertension; 2009 Sep 29; 54(3):591-7. PubMed ID: 19564547
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy.
    Sakata Y, Masuyama T, Yamamoto K, Doi R, Mano T, Kuzuya T, Miwa T, Takeda H, Hori M.
    J Am Coll Cardiol; 2001 Jan 29; 37(1):293-9. PubMed ID: 11153754
    [Abstract] [Full Text] [Related]

  • 14. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
    Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, Iwao H.
    Circulation; 2001 Jan 02; 103(1):148-54. PubMed ID: 11136700
    [Abstract] [Full Text] [Related]

  • 15. [Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension].
    Shimoyama M, Hayashi D, Zou Y, Takimoto E, Mizukami M, Monzen K, Yazaki Y, Nagai R, Komuro I.
    J Cardiol; 2001 Feb 02; 37(2):114-8. PubMed ID: 11255695
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats.
    Iwanaga Y, Kihara Y, Hasegawa K, Inagaki K, Yoneda T, Kaburagi S, Araki M, Sasayama S.
    Circulation; 1998 Nov 10; 98(19):2065-73. PubMed ID: 9808606
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, Dai ZK, Chen WY, Chen YF, Lee AS.
    Cardiovasc Diabetol; 2019 Apr 01; 18(1):45. PubMed ID: 30935417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.